- Home
- ATYR vs MCRB Comparison
ATYR vs MCRB Comparison
Compare ATYR & MCRB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ATYR | MCRB |
|---|---|---|
| Founded | 2005 | 2010 |
| Country | United States | United States |
| Employees | N/A | 66 |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 49.2M | 41.2M |
| IPO Year | 2015 | 2015 |
Fundamental Metrics
Financial Performance| Metric | ATYR | MCRB |
|---|---|---|
| Price | $0.36 | $4.00 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 9 | 2 |
| Target Price | $3.67 | ★ $14.00 |
| AVG Volume (30 Days) | ★ 728.9K | 48.4K |
| Earning Date | 05-01-2026 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 6.98 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | $190,000.00 | ★ $789,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.37 | $4.01 |
| 52 Week High | $1.12 | $29.98 |
Technical Indicators
Market Signals| Indicator | ATYR | MCRB |
|---|---|---|
| Relative Strength Index (RSI) | 25.85 | 35.21 |
| Support Level | N/A | N/A |
| Resistance Level | $0.59 | $5.80 |
| Average True Range (ATR) | 0.03 | 0.35 |
| MACD | -0.01 | -0.12 |
| Stochastic Oscillator | 2.13 | 9.40 |
Price Performance
Historical ComparisonAbout ATYR aTyr Pharma Inc.
aTyr Pharma Inc is a clinical-stage biotechnology company focused on developing therapies for fibrosis and inflammatory conditions. Its research leverages tRNA synthetase biology to identify potential therapeutic targets. The company's discovery platform uses a proprietary library of domains derived from tRNA synthetases to explore signaling pathways. Its flagship clinical candidate, efzofitimod, is a novel biologic immunomodulatory in development for the treatment of interstitial lung disease (ILD).
About MCRB Seres Therapeutics Inc.
Seres Therapeutics Inc is a clinical-stage biotechnology company focused on the development of live biotherapeutic candidates. Its pipeline includes candidates such as SER-155 and SER-603, aimed at preventing and treating bacterial infections, antimicrobial resistance, and gastrointestinal immune diseases. The company operates as a single reportable segment, mainly developing microbiome-based therapies targeting bacterial infections, antimicrobial resistance, and gastrointestinal immune diseases.